Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03583372 · ClinicalTrials.gov registry record · Phase 3
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
A Phase 3 study, sponsored by Urovant Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 506
- Enrollment target
NCT03583372 is a Phase 3 study that has completed, run by Urovant Sciences. The registered enrollment target is 506 participants.
The verdict
NCT03583372, a Phase 3 study, has completed, sponsored by Urovant Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 506 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in participants with OAB for up to 52 weeks.
Interventions
- DRUG Vibegron
- DRUG Tolterodine Tartrate ER
- DRUG placebos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 506 participants |
| Start Date | 2018-06-14 |
| Est. Completion | 2019-07-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03583372
The ClinicalTrials.gov registry entry for NCT03583372 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 506 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Urovant Sciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vibegron is the first listed.
NCT03583372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03583372 about?
NCT03583372 is a clinical study titled "An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).". This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in participants with OAB for up to 52 weeks.
What is the current status of trial NCT03583372?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 506 participants. The study started on 2018-06-14. Estimated completion is 2019-07-25.
What interventions are being tested in trial NCT03583372?
The interventions under investigation include: Vibegron (DRUG), Tolterodine Tartrate ER (DRUG), placebos (DRUG).
Who is sponsoring clinical trial NCT03583372?
This trial is sponsored by Urovant Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.